Chimeric antigen receptor T-cell therapy for melanoma

References

• Degenhardt Y, Huang J, Greshock J, et al. Distinct MHC gene expression patterns during progression of melanoma.. Genes Chromosomes Cancer. 2010 Feb;49(2):144–154.
   PubMed Web of Science ®Google Scholar
• Cichorek M, Wachulska M, Stasiewicz A, et al. Skin melanocytes: biology and development. Postepy Dermatol Alergol. 2013 Feb;30(1):30–41.
   PubMed Web of Science ®Google Scholar
• Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013 Sep;11(2):81–91.
   PubMedGoogle Scholar
• Bandarchi B, Ma L, Navab R, et al. From melanocyte to metastatic malignant melanoma. Dermatol Res Pract. 2010;2010:583748.
   Google Scholar
• Rabbie R, Ferguson P, Molina‐Aguilar C, et al. Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 2019;247(5):539–551.
   PubMed Web of Science ®Google Scholar
• Rastrelli M, Tropea S, Rossi CR, et al. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo. 2014 Nov-Dec;28(6):1005–1011.
   PubMed Web of Science ®Google Scholar
• Khan AQ, Travers JB, Kemp MG. Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. Environ Mol Mutagen. 2018;59(5):438–460.
   PubMed Web of Science ®Google Scholar
• Gerber B, Mathys P, Moser M, et al. Ultraviolet Emission Spectra of Sunbeds. Photochem Photobiol. 2002;76(6):664–668.
   PubMed Web of Science ®Google Scholar
• Bataille V, Boniol M, De Vries E, et al. A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer. 2005;41(14):2141–2149.
   PubMed Web of Science ®Google Scholar
• Berwick M, Buller DB, Cust A, et al. Melanoma epidemiology and prevention. Melanoma: Springer; 2016. p. 17–49.
   Google Scholar
• Kosary CL, Altekruse SF, Ruhl J, et al. Clinical and prognostic factors for melanoma of the skin using SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014;120:3807–3814.
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Stratigos A. Emerging trends in the epidemiology of melanoma. Br J Dermatol. 2014;170(1):11–19.
   PubMed Web of Science ®Google Scholar
• Coory M, Baade P, Aitken J, et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982–2002. Cancer Causes Control. 2006;17(1):21–27.
   PubMed Web of Science ®Google Scholar
• Marrett LD, Nguyen HL, Armstrong BK. Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983–1996. Int J Cancer. 2001;92(3):457–462.
   PubMed Web of Science ®Google Scholar
• Jemal A, Devesa SS, Hartge P, et al. Recent trends in cutaneous melanoma incidence among whites in the United States. JNCI Journal of the National Cancer Institute. 2001;93(9):678–683.
   PubMedGoogle Scholar
• Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5):S17. e1-S17. e11.
   Web of Science ®Google Scholar
• Ulmer MJ, Tonita JM, Hull PR. Trends in invasive cutaneous melanoma in Saskatchewan 1970–1999. Journal of Cutaneous Medicine and Surgery: Incorporating Medical and Surgical Dermatology. 2003;7(6):433–442.
   PubMed Web of Science ®Google Scholar
• MacKie RM, Bray CA, Hole DJ, et al. Incidence of and survival from malignant melanoma in Scotland: an epidemiological study. Lancet. 2002;360(9333):587–591.
   PubMed Web of Science ®Google Scholar
• Lasithiotakis KG, Leiter U, Gorkievicz R, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer. 2006;107(6):1331–1339.
   PubMed Web of Science ®Google Scholar
• Stang A, Pukkala E, Sankila R, et al. Time trend analysis of the skin melanoma incidence of Finland from 1953 through 2003 including 16,414 cases. Int J Cancer. 2006;119(2):380–384.
   PubMed Web of Science ®Google Scholar
• Lipsker D, Engel F, Cribier B, et al. Trends in melanoma epidemiology suggest three different types of melanoma. Br J Dermatol. 2007;157(2):338–343.
   PubMed Web of Science ®Google Scholar
• De Vries E, Bray FI, Coebergh JWW, et al. Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer. 2003;107(1):119–126.
   PubMed Web of Science ®Google Scholar
• Shen W, Sakamoto N, Yang L. Melanoma-specific mortality and competing mortality in patients with non-metastatic malignant melanoma: a population-based analysis. BMC Cancer. 2016;16(1):413.
   PubMed Web of Science ®Google Scholar
• Matthews NH, Li W-Q, Qureshi AA, et al. Epidemiology of melanoma. Cutaneous melanoma: etiology and therapy [Internet]. Australia: Codon Publications; 2017.
   Google Scholar
• Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview.. Oncology (Williston Park). 2009 May;23(6):488–496.
   PubMed Web of Science ®Google Scholar
• Tsao H, Olazagasti JM, Cordoro KM, et al. Early detection of melanoma: reviewing the ABCDEs. J Am Acad Dermatol. 2015 Apr;72(4):717–723.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Lee SJ, Hodi FS, et al. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: north American Intergroup E1609. J Clin Oncol. 2020 Feb 20;38(6):567–575.
   PubMed Web of Science ®Google Scholar
• McKean MA, Amaria RN. Multidisciplinary treatment strategies in high-risk resectable melanoma: role of adjuvant and neoadjuvant therapy. Cancer Treat Rev. 2018;70:144–153.
   PubMed Web of Science ®Google Scholar
• Daneshvar F, Salehi F, Karimi M, et al. Combined X-ray radiotherapy and laser photothermal therapy of melanoma cancer cells using dual-sensitization of platinum nanoparticles. Journal of Photochemistry and Photobiology. B, Biology. 2020;203:111737.
   PubMed Web of Science ®Google Scholar
• Raigani S, Cohen S, Boland GM. The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. Curr Oncol Rep. 2017 Mar;19(3):17.
   PubMed Web of Science ®Google Scholar
• Si X, Gao Z, Xu F, et al. SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma. Mol Carcinog. 2019;59(3):257–264.
   PubMed Web of Science ®Google Scholar
• Joshi S, Durden DL. Combinatorial Approach to Improve Cancer Immunotherapy: rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. J Oncol. 2019;2019:5245034.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NPJS. Adoptive cell transfer as personalized immunotherapy for human cancer. Science (New York, N.Y.). 2015;348(6230):62–68.
   PubMed Web of Science ®Google Scholar
• Krug C, Birkholz K, Paulus A, et al. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. Cancer Immunology, Immunotherapy : CII. 2015;64(12):1623–1635.
   PubMed Web of Science ®Google Scholar
• Borrie AE, Vareki SM. T Lymphocyte–Based Cancer Immunotherapeutics. Int Rev Cell Mol Biol. 2018;341:201–276. Elsevier;
   PubMed Web of Science ®Google Scholar
• Scarfò I, Maus MV. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer. 2017;5(1):28.
   PubMed Web of Science ®Google Scholar
• Ritchie DS, Neeson PJ, Khot A, et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol Ther. 2013;21(11):2122–2129.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-? immunotherapy. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2001;92(2):369–376.
   Google Scholar
• Kalaitsidou M, Kueberuwa G, Schütt A, et al. CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy. 2015;7(5):487–497.
   PubMed Web of Science ®Google Scholar
• Tokarew N, Ogonek J, Endres S, et al. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26–37.
   PubMed Web of Science ®Google Scholar
• Zhang J, Medeiros LJ, Young KH. Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol. 2018;8:351.
   PubMed Web of Science ®Google Scholar
• Stock S, Schmitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019 Dec 10;20(24):6223.
   Web of Science ®Google Scholar
• Akhavan D, Alizadeh D, Wang D, et al. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019 Jul;290(1):60–84.
   PubMed Web of Science ®Google Scholar
• Wei J, Han X, Bo J, et al. Target selection for CAR-T therapy. J Hematol Oncol. 2019;12(1):62.
   Google Scholar
• Zitelli JA, Brown CD, Hanusa BH. Surgical margins for excision of primary cutaneous melanoma. J Am Acad Dermatol. 1997;37(3):422–429.
   PubMed Web of Science ®Google Scholar
• Krementz ET, Ryan RF. Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience. Ann Surg. 1972;175(6):900.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Radiation treatment of malignant melanoma. International Journal of Radiation Oncology*Biology*Physics. 1980;6(1):41–44.
   Web of Science ®Google Scholar
• Rosner S, Kwong E, Shoushtari AN, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med. 2018;7(3):690–697.
   PubMed Web of Science ®Google Scholar
• Sweetlove M, Wrightson E, Kolekar S, et al. Inhibitors of pan-PI3K signaling synergize with BRAF or MEK inhibitors to prevent BRAF-mutant melanoma cell growth. Front Oncol. 2015;5:135.
   PubMed Web of Science ®Google Scholar
• Sabel MS, Arora A. The role of the surgeon in the management of melanoma. Minerva Chir. 2006 Apr;61(2):141–154.
   PubMedGoogle Scholar
• Mohr P, Kiecker F, Soriano V, et al. Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review. Melanoma Manag. 2019 Oct 4;6(4):MMT33.
   PubMedGoogle Scholar
• Young SE, Martinez SR, Essner R. The role of surgery in treatment of stage IV melanoma. Journal of Surgical Oncology. 2006;94(4):344–351.
   PubMed Web of Science ®Google Scholar
• Buzaid A, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998;8(6):549–556.
   PubMed Web of Science ®Google Scholar
• Bibault J-E, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. Radiat Oncol. 2011;6(1):12.
   PubMed Web of Science ®Google Scholar
• Veronesi U, Adamus J, Aubert C, et al. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med. 1982;307(15):913–916.
   PubMed Web of Science ®Google Scholar
• Fletcher WS, Pommier RF, Lum S, et al. Surgical treatment of metastatic melanoma. Am J Surg. 1998;175(5):413–417.
   PubMed Web of Science ®Google Scholar
• Eustace AJ, Crown J, Clynes M, et al. Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J Transl Med. 2008;6(1):53.
   PubMed Web of Science ®Google Scholar
• Silk AW, Kaufman HL, Curti B, et al. High-dose ipilimumab and high-dose interleukin-2 for patients with advanced melanoma. Frontiers in Oncology. 2020;9(1483): 10.3389/fonc.2019.01483
   PubMed Web of Science ®Google Scholar
• Megahed AI, Koon H. What is the role of chemotherapy in the treatment of melanoma? Current Treatment Options in Oncology. 2014;15(2):321–335.
   PubMed Web of Science ®Google Scholar
• Wilson MA, Schuchter LM. Chemotherapy for melanoma. In: Kaufman H, Mehnert J, editors. Melanoma. Vol. 167. Cham: Springer; 2016. p. 209–229.
   Google Scholar
• McNeil EM, Astell KR, Ritchie A-M, et al. Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance. DNA Repair (Amst). 2015;31:19–28.
   PubMed Web of Science ®Google Scholar
• Lattanzi S, Tosteson T, Chertoff J, et al. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res. 1995;5(5):365–369.
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple‐drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64(10):2024–2029.
   PubMed Web of Science ®Google Scholar
• Agarwala S, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. Journal of Clinical Oncology. 2007;25(18_suppl):8510.
   Web of Science ®Google Scholar
• Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J. 2014;20(1):18.
   PubMed Web of Science ®Google Scholar
• Legha S, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-α. Ann Oncol. 1996;7(8):827–835.
   PubMed Web of Science ®Google Scholar
• Hauschild A, Garbe C, Stolz W, et al. Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG). Br J Cancer. 2001;84(8):1036–1042.
   PubMed Web of Science ®Google Scholar
• Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J clin oncol. 2005;23(35):9001–9007.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM, Gooding WE, et al. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J clin oncol. 2007;25(25):3802–3807.
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14(17):5610–5618.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–451.
   PubMed Web of Science ®Google Scholar
• Falkson CI, Ibrahim J, Kirkwood JM, et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J clin oncol. 1998;16(5):1743–1751.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. J clin oncol. 1999;17(3):968.
   PubMed Web of Science ®Google Scholar
• Ridolfi R, Chiarion-Sileni V, Guida M, et al. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J clin oncol. 2002;20(6):1600–1607.
   PubMed Web of Science ®Google Scholar
• Glover D, Glick JH, Weiler C, et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. J clin oncol. 1987;5(4):574–578.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kitabatake K, Abe R, et al. Involvement of A2B Receptor in DNA Damage Response and Radiosensitizing Effect of A2B Receptor Antagonists on Mouse B16 Melanoma. Biol Pharm Bull. 2020 Mar 1;43(3):516–525.
   PubMed Web of Science ®Google Scholar
• Bonnen MD, Ballo MT, Myers JN, et al. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004;100(2):383–389.
   PubMed Web of Science ®Google Scholar
• Strojan PJR. oncology. Role of Radiotherapy in Melanoma Management. 2010;44(1):1–12.
   Google Scholar
• Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol. 2010 Mar;44(1):1–12.
   PubMed Web of Science ®Google Scholar
• Thariat J, Salleron J, Maschi C, et al. Oncologic and visual outcomes after postoperative proton therapy of localized conjunctival melanomas. Radiat Oncol. 2019 Dec 27;14(1):239.
   PubMed Web of Science ®Google Scholar
• D’Andrea MA, Reddy GKJROJ. Extracranial systemic antitumor response through the abscopal effect induced by brain radiation in a patient with metastatic melanoma. Radiation Oncology Journal. 2019;37(4):302.
   PubMed Web of Science ®Google Scholar
• Park S, Lee WJ, Park S, et al. Reversibly pH-responsive gold nanoparticles and their applications for photothermal cancer therapy. Sci Rep. 2019;9(1):1–9.
   Google Scholar
• Seyedin SN, Schoenhals JE, Lee DA, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7(9):967–980.
   PubMed Web of Science ®Google Scholar
• Wernicke AG, Polce S, Parashar B. Role of Radiation in the Era of Effective Systemic Therapy for Melanoma. Surg Clin North Am. 2020 Feb;100(1):189–199.
   PubMed Web of Science ®Google Scholar
• Franklin C, Livingstone E, Roesch A, et al. Immunotherapy in melanoma: recent advances and future directions. Eur J Surg Oncol. 2017 Mar;43(3):604–611.
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte–associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12(12):1005–1016.
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD, et al. Improving CART-cell therapy of solid tumors with oncolytic virus–driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–616.
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Dreno B, Jantscheff P, et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther. 2002;9(3):289–295.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen–G serum level is elevated in melanoma patients and is further increased by interferon‐α immunotherapy. Cancer: Interdiscip Int J Am Cancer Soc. 2001;92(2):369–376.
   Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Madore J, Vilain RE, Menzies AM, et al. PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L 1 clinical trials. Pigment Cell Melanoma Res. 2015;28(3):245–253.
   PubMed Web of Science ®Google Scholar
• Baghdadi M, Nagao H, Yoshiyama H, et al. Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. Cancer Immunol Immunother. 2013;62(4):629–637.
   PubMed Web of Science ®Google Scholar
• Strome SE, Martin B, Flies D, et al. Enhanced therapeutic potential of adoptive immunotherapy by in vitro CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. J Immunother. 2000;23(4):430–437.
   PubMed Web of Science ®Google Scholar
• Fujiwara S, Nagai H, Shimoura N, et al. Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. J Invest Dermatol. 2014;134(7):1884–1892.
   PubMed Web of Science ®Google Scholar
• Holtzhausen A, Zhao F, Evans KS, et al. Melanoma-derived Wnt5a promotes local dendritic-cell expression of IDO and immunotolerance: opportunities for pharmacologic enhancement of immunotherapy. Cancer Immunol Res. 2015;3(9):1082–1095.
   PubMed Web of Science ®Google Scholar
• Naumova E, Mihaylova A, Stoitchkov K, et al. Genetic polymorphism of NK receptors and their ligands in melanoma patients: prevalence of inhibitory over activating signals. Cancer Immunol Immunother. 2005;54(2):172–178.
   PubMed Web of Science ®Google Scholar
• Wang JJ, Burger P, Taube J, et al. PD-L1, PD-1, LAG-3, and TIM-3 in Melanoma: expression in Brain Metastases Compared to Corresponding Extracranial Tumors. Cureus. 2019;11:12.
   Web of Science ®Google Scholar
• Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. J Immunother Cancer. 2019;7(1):49.
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Chosidow O, Wechsler J, et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J Am Acad Dermatol. 1993;28(1):66–70.
   PubMed Web of Science ®Google Scholar
• Curti B, Crittenden M, Seung SK, et al. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma. J Immunother Cancer. 2020;8:1.
   Google Scholar
• Trinh VA, Zobniw C, Hwu W-J. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma. Expert Opin Drug Saf. 2017;16(8):933–940.
   Google Scholar
• Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther. 2015;37(4):764–782.
   PubMed Web of Science ®Google Scholar
• Chikuma SCTLA. 4, an essential immune-checkpoint for T-cell activation. Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity: Springer. 2017; 99–126.
   Google Scholar
• Weber JS, O’Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol.  2008;26(36):5950–5956.
   Google Scholar
• Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009;27(7):1075–1081.
   Google Scholar
• Callahan MK, Kluger H, Postow MA, et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J Clin Oncol. 2018;36(4):391.
   Google Scholar
• Banaszynski M, Kolesar J-S. Vemurafenib and ipilimumab: new agents for metastatic melanoma. Am J Health Syst Pharm. 2013;70(14):1205–1210.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117. 2014/09/20/
   PubMed Web of Science ®Google Scholar
• Weber JS. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
   Google Scholar
• Rodríguez-Cerdeira C, Carnero Gregorio M, López-Barcenas A, et al. Advances in immunotherapy for melanoma: a comprehensive review. 2017;2017:3264217.
   Google Scholar
• Gough MJ, Crittenden MR, Sarff M, et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control following surgical or radiation therapy of cancer in mice. J Immunother. 2010;33(8):798.
   PubMed Web of Science ®Google Scholar
• Peng W, Williams LJ, Xu C, et al. Anti-OX40 antibody directly enhances the function of tumor-reactive CD8+ T cells and synergizes with PI3Kβ inhibition in PTEN loss melanoma. Clin Cancer Res. 2019;25(21):6406–6416.
   Google Scholar
• Kvarnhammar AM, Veitonmäki N, Hägerbrand K, et al. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation. J Immunother Cancer. 2019;7(1):1–14.
   Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475. Elsevier;
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.. The New England Journal of Medicine. 2011;364(22):2119–2127.
   PubMed Web of Science ®Google Scholar
• Butterfield LH, Vujanovic L, Santos PM, et al. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma. J Immunother Cancer. 2019;7(1):113.
   Google Scholar
• Sheng L, Chen X, Wang Q, et al. Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines.. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2020;125(109966): 10.1016/j.biopha.2020.109966
   PubMed Web of Science ®Google Scholar
• Smith TT, Moffett HF, Stephan SB, et al. Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors.. The Journal of Clinical Investigation. 2017;127(6):2176–2191.
   PubMed Web of Science ®Google Scholar
• Grenier JM, Yeung ST, Qiu Z, et al. Combining adoptive cell therapy with cytomegalovirus-based vaccine is protective against solid skin tumors. Front Immunol. 2018;8:1993.
   PubMed Web of Science ®Google Scholar
• Solari N, Spagnolo F, Ponte E, et al. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent. J Surg Oncol. 2014;109(3):270–274.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.. 2000;6 Suppl 1:S11–4. The Cancer Journal from Scientific American.
   PubMed Web of Science ®Google Scholar
• Richards J, Bedikian A, Gonzalez R, et al. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. J clin oncol. 2005;23(16_suppl):7543.
   Google Scholar
• Sun J, Zager JS, Eroglu Z. Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy. Onco Targets Ther. 2018;11:9081.
   PubMed Web of Science ®Google Scholar
• Guo J, Carvajal R, Dummer R, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. Ann Oncol. 2017;28(6):1380–1387.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med. 2015;372(4):320–330.
   PubMed Web of Science ®Google Scholar
• Ott PA, Pavlick AC, Johnson DB, et al. A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019;125(7):1113–1123.
   PubMed Web of Science ®Google Scholar
• Keilholz U, Mehnert JM, Bauer S, et al. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial. J Immunother Cancer. 2019;7(1):12.
   PubMed Web of Science ®Google Scholar
• Yamazaki N, Takenouchi T, Fujimoto M, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79(4):651–660.
   PubMed Web of Science ®Google Scholar
• Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. Cancer Treat Rep. 1982;66(1):31–35.
   PubMedGoogle Scholar
• Evans LM, Casper ES, Rosenbluth R. Phase I] trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep. 1987;71(2):171–172.
   PubMedGoogle Scholar
• Shah S, Luke JJ, Jacene HA, et al. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018;28(6):605–610.
   PubMed Web of Science ®Google Scholar
• Olbryt M, Piglowski W, Rajczykowski M, et al. Genetic Profiling of Advanced Melanoma: candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy. Target Oncol. 2020 Feb;15(1):101–113.
   PubMed Web of Science ®Google Scholar
• Croce L, Coperchini F, Magri F, et al. The multifaceted anti-cancer effects of BRAF-inhibitors. Oncotarget. 2019 Nov 12;10(61):6623–6640.
   PubMedGoogle Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
   PubMed Web of Science ®Google Scholar
• Poduje S, Brozic JM, Prkacin I, et al. Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma. Dermatol Ther. 2020 Jan;33(1):e13174.
   PubMed Web of Science ®Google Scholar
• Koya RC, Mok S, Otte N, et al. BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 2012;72(16):3928–3937.
   PubMed Web of Science ®Google Scholar
• Lo AS, Ma Q, Liu DL, et al. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res. 2010 May 15;16(10):2769–2780.
   PubMed Web of Science ®Google Scholar
• Perica K, Varela JC, Oelke M, et al. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015 Jan;6(1):e0004.
   PubMed Web of Science ®Google Scholar
• Ellebaek E, Iversen TZ, Junker N, et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med. 2012;10(1):169.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, et al. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 2003;26(4):332.
   Google Scholar
• Poch M, Hall M, Joerger A, et al. Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer. Oncoimmunology. 2018;7(9):e1476816.
   PubMed Web of Science ®Google Scholar
• Duong CP, Yong CS, Kershaw MH, et al. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol Immunol. 2015 Oct;67(2 Pt A):46–57.
   PubMed Web of Science ®Google Scholar
• Shen X, Zhou J, Hathcock KS, et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J Immunother. 2007;30(1):123.
   PubMed Web of Science ®Google Scholar
• Duong CP, Yong CS, Kershaw MH, et al. Cancer immunotherapy utilizing gene-modified T cells: from the bench to the clinic. Mol Immunol. 2015;67(2):46–57.
   PubMed Web of Science ®Google Scholar
• Sun Q, Zhang X, Wang L, et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death Dis. 2019 Jun 17;10(7):475.
   PubMed Web of Science ®Google Scholar
• He Q, Jiang X, Zhou X, et al. Targeting cancers through TCR-peptide/MHC interactions. J Hematol Oncol. 2019;12(1):1–17.
   Google Scholar
• Merhavi-Shoham E, Itzhaki O, Markel G, et al. Adoptive Cell Therapy for Metastatic Melanoma. Cancer J. 2017 Jan/Feb;23(1):48–53.
   PubMed Web of Science ®Google Scholar
• Govers C, Sebestyen Z, Coccoris M, et al. T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing. Trends Mol Med. 2010 Feb;16(2):77–87.
   PubMed Web of Science ®Google Scholar
• Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows Arch. 2019 Apr;474(4):449–461.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ping J, Huang Z, et al. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead 2020; 2020:
   Google Scholar
• Goff SL, Morgan RA, Yang JC, et al. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019;42(4):126–135.
   PubMed Web of Science ®Google Scholar
• Xu J, Wang Q, Xu H, et al. Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma. J Hematol Oncol. 2018;11(1):1–9.
   PubMed Web of Science ®Google Scholar
• Haso W, Lee DW, Shah NN. et al. Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood, the Journal of the American Society of Hematology. 2013;121(7):1165–1174.
   Google Scholar
• Hong H, Stastny M, Brown C, et al. Diverse solid tumors expressing a restricted epitope of L1-CAM can be targeted by chimeric antigen receptor redirected T lymphocytes. J Immunother. 2014;37(2):93–104.
   PubMed Web of Science ®Google Scholar
• Harrer DC, Schuler G, Dorrie J, et al. CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia. Int J Mol Sci. 2019 Jun 5;20(11):2764.
   Web of Science ®Google Scholar
• Geldres C, Savoldo B, Hoyos V, et al. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2014;20(4):962–971.
   PubMed Web of Science ®Google Scholar
• Harrer DC, Dörrie J, Schaft N. CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges. Int J Mol Sci. 2019;20(23):5942.
   Google Scholar
• Krishnamurthy J, Rabinovich BA, Mi T, et al. Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma. Clin Cancer Res. 2015 Jul 15;21(14):3241–3251.
   PubMed Web of Science ®Google Scholar
• Forsberg EM, Lindberg MF, Jespersen H, et al. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research. 2019;79(5):899–904.
   PubMed Web of Science ®Google Scholar
• Yu J, Wu X, Yan J, et al. Anti-GD2/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018 Jan 3;11(1):1.
   PubMed Web of Science ®Google Scholar
• Kandil D, Leiman G, Allegretta M, et al. Glypican‐3 protein expression in primary and metastatic melanoma: a combined immunohistochemistry and immunocytochemistry study. Cancer Cytopathology: A Journal of the American Cancer Society. 2009;117(4):271–278.
   PubMed Web of Science ®Google Scholar
• Kan S, Konishi E, Arita T, et al. Podoplanin expression in cancer‐associated fibroblasts predicts aggressive behavior in melanoma. J Cutan Pathol. 2014;41(7):561–567.
   PubMed Web of Science ®Google Scholar
• Kageshita T, Funasaka Y, Ichihashi M, et al. Tissue factor expression and serum level in patients with melanoma does not correlate with disease progression. Pigment Cell Res. 2001;14(3):195–200.
   PubMedGoogle Scholar
• Fisher J, Abramowski P, Don NDW, et al. Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther. 2017;25(5):1234–1247.
   PubMed Web of Science ®Google Scholar
• Theobald M. Current Immunotherapeutic Strategies in Cancer. Cham, Switzerland: Springer; 2020.
   Google Scholar
• Akahori Y, Wang L, Yoneyama M, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.. Blood. 2018;132(11):1134–1145.
   PubMed Web of Science ®Google Scholar
• Srivastava S, Riddell SR. Chimeric Antigen Receptor T Cell Therapy: challenges to Bench-to-Bedside Efficacy. J Immunol. 2018 Jan 15;200(2):459–468.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Chen Y, Francisco NM, et al. The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharm Sin B. 2018 Jul;8(4):539–551.
   PubMed Web of Science ®Google Scholar
• Krug C, Birkholz K, Paulus A, et al. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone. Cancer Immunol Immunother. 2015 Dec;64(12):1623–1635.
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Yu Z, Theoret MR, et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.. The Journal of Clinical Investigation. 2010;120(11):3953–3968.
   PubMed Web of Science ®Google Scholar
• Chinnasamy D, Tran E, Yu Z, et al. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.. Cancer Research. 2013;73(11):3371–3380.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT01218867. 2020 December, 20
   Google Scholar
• Gargett T, Yu W, Dotti G, et al. GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.. Molecular Therapy : The Journal of the American Society of Gene Therapy. 2016;24(6):1135–1149.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT02107963. December 20, 2020 [updated 2020 Dec 20].
   Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT02482532. December 20, 2020.
   Google Scholar
• Shum T, Omer B, Tashiro H, et al. Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.. Cancer Discovery. 2017;7(11):1238–1247.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT03635632. December 20, 2020.
   Google Scholar
• Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas.. Neuro-oncology. 2018;20(1):55–65.
   PubMed Web of Science ®Google Scholar
• Park YP, Jin L, Bennett KB, et al. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.. Oral Oncology. 2018;78:145–150.
   PubMed Web of Science ®Google Scholar
• Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. 2020;10(17):7622.
   Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT02830724. December 20, 2020.
   Google Scholar
• Gardner RA, Ceppi F, Rivers J, et al. Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.. Blood. 2019;134(24):2149–2158.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT04483778. December 20, 2020.
   Google Scholar
• Lock D, Mockel-Tenbrinck N, Drechsel K, et al. Automated Manufacturing of Potent CD20-Directed Chimeric Antigen Receptor T Cells for Clinical Use.. Human Gene Therapy. 2017;28(10):914–925.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT03893019. December 20, 2020.
   Google Scholar
• Bianchi V, Bulek A, Fuller A, et al. A Molecular Switch Abrogates Glycoprotein 100 (gp100) T-cell Receptor (TCR) Targeting of a Human Melanoma Antigen.. The Journal of Biological Chemistry. 2016;291(17):8951–8959.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT03649529. December 20, 2020
   Google Scholar
• Raza A, Merhi M, Inchakalody VP, et al. Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy. J Transl Med. 2020;18(1):140.
   Google Scholar
• Maus MV, Plotkin J, Jakka G, et al. An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity.. Molecular Therapy Oncolytics. 2016;3(16023):1–9.
   PubMed Web of Science ®Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT03638206. December 20, 2020.
   Google Scholar
• https://www.clinicaltrials.gov/ct2/show/NCT04119024. December 20, 2020.
   Google Scholar
• Hegde M, Mukherjee M, Grada Z, et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.. The Journal of Clinical Investigation. 2016;126(8):3036–3052.
   PubMed Web of Science ®Google Scholar
• Kong S, Sengupta S, Tyler B, et al. Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. 2012;18(21):5949–5960.
   PubMed Web of Science ®Google Scholar
• Stock S, Schmitt M, Sellner L. Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. Int J Mol Sci. 2019;20(24):6223.
   Web of Science ®Google Scholar
• Cherkassky L, Morello A, Villena-Vargas J, et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016 Aug 1;126(8):3130–3144.
   PubMed Web of Science ®Google Scholar
• Maus MV, June CH. Making better chimeric antigen receptors for adoptive T-cell therapy. AACR. 2016;22(8):1875–1884.
   Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018 Oct;36(9):847–856.
   PubMed Web of Science ®Google Scholar
• Hoogi S, Eisenberg V, Mayer S, et al. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function. Journal for Immunotherapy of Cancer. 2019;7(1):243.
   PubMed Web of Science ®Google Scholar
• Mahnke K, Enk A. TIGIT-CD155 interactions in melanoma: a novel co-inhibitory pathway with potential for clinical intervention. The Journal of Investigative Dermatology. 2016;136(1):9–11.
   PubMed Web of Science ®Google Scholar
• Wiesinger M, März J, Kummer M, et al. Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance. Cancers. 2019;11(8):1198.
   Web of Science ®Google Scholar
• Bommhardt U, Schraven B, Simeoni L. Beyond TCR signaling: emerging functions of Lck in cancer and immunotherapy. International Journal of Molecular Sciences. 2019;20(14):3500.
   Web of Science ®Google Scholar
• Perna SK, Pagliara D, Mahendravada A, et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res. 2014;20(1):131–139.
   PubMed Web of Science ®Google Scholar